NIH R01 · 2025
Survival of chronic myeloid leukemia (CML) patients with a sustained major molecular response to Bcr-abl- tyrosine kinase inhibitors (TKIs) may approach age matched controls. Attempts at therapy discontinuation are standard of care for such patients, and 40-50% sustain a therapy free remission (TFR). However, there are no clinical tools that reliably predict TFR duration for an individual. Prior single cell RNA-sequencing (scRNA-Seq) defined a TKI sensitive, proliferative subset of CML-leukemia stem cells (LSCs) and a relatively quiescent subset that persists during TKI treatment. Mechanisms for emergence of these subpopulations are unclear. In preliminary studies, we identified an…
From the public funding record at NIH RePORTER. Describes the funded project, not the reviews below.